• Issue

    Hematological Oncology: Volume 41, Issue 3

    291-602
    August 2023
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 291-292
  • First Published: 09 August 2023

REVIEWS

Richter transformation in Chronic Lymphocytic Leukemia

Idanna Innocenti,  Giulia Benintende,  Annamaria Tomasso,  Alberto Fresa,  Francesco Autore,  Luigi Maria Larocca,  Luca Laurenti, 
  • Pages: 293-300
  • First Published: 26 November 2022
Open Access

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Han-Yu Cao,  Ling Li,  Sheng-Li Xue,  Hai-Ping Dai, 
  • Pages: 301-309
  • First Published: 17 October 2022

TAFRO syndrome: A disease that known is half cured

Tingting Chen,  Chun Feng,  Xinyou Zhang,  Jihao Zhou, 
  • Pages: 310-322
  • First Published: 23 September 2022

The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma

Kelechi C. Eseonu,  Jaykar R. Panchmatia,  Matthew J. Streetly,  Jonathan N. Grauer,  Bahram Fakouri, 
  • Pages: 323-334
  • First Published: 28 November 2022

ORIGINAL ARTICLES

Open Access

Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients

Enrico Derenzini,  Angela Gueli,  Alessandra Risso,  Riccardo Bruna,  Daniela Gottardi,  Alessandro Cignetti,  Stefano Pileri,  Enrico V. Avvedimento,  Corrado Tarella, 
  • Pages: 335-342
  • First Published: 19 December 2022
Open Access

Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study

Giovanni Manfredi Assanto,  Alice Di Rocco,  Francesco Malfona,  Marcello Capriata,  Ilaria Del Giudice,  Luigi Petrucci,  Paola Girardi,  Gianna Maria D’Elia,  Maurizio Martelli,  Giuseppe Gentile,  Alessandra Micozzi,  Alessandro Pulsoni, 
  • Pages: 343-353
  • First Published: 15 December 2022
Open Access

Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database

Satoshi Dote,  Ryo Inose,  Ryota Goto,  Yuka Kobayashi,  Yuichi Muraki, 
  • Pages: 354-362
  • First Published: 15 February 2023
Open Access

Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study

Veronica Mattiello,  Angelica Barone,  Diana Giannarelli,  Alessandro Noto,  Nicola Cecchi,  Nicolò Rampi,  Ramona Cassin,  Gianluigi Reda, 
  • Pages: 363-370
  • First Published: 10 February 2023

Malnutrition diagnosed by GLIM criteria better predicts long-term outcomes for patients with non-Hodgkin's lymphoma: A prospective multicenter cohort study

Yuanlin Zou,  Hongxia Xu,  Quanjun Lyu,  Min Weng,  Jiuwei Cui,  Hanping Shi,  Chunhua Song, 
  • Pages: 371-379
  • First Published: 23 November 2022

Prognostic value of prognostic nutritional index on extranodal natural killer/T-cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working Group

Ziyuan Shen,  Shuo Zhang,  Xicheng Chen,  Qing Zhang,  Yaxue Jiao,  Yuye Shi,  Hao Zhang,  Jingjing Ye,  Ling Wang,  Taigang Zhu,  Yuqing Miao,  Liang Wang,  Guoqi Cai,  Wei Sang, 
  • Pages: 380-388
  • First Published: 21 January 2023

Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation

Takashi Tanaka,  Yoshihiro Inamoto,  Ayumu Ito,  Mizuki Watanabe,  Wataru Takeda,  Jun Aoki,  Sung-Won Kim,  Takahiro Fukuda, 
  • Pages: 389-395
  • First Published: 13 December 2022

Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study

Jing Tian,  Miaowang Hao,  Qiang Liu,  Fang Xiao,  Yuanchun Li,  Meiying Qi,  Jing Gao,  Li Liu,  Dandan Yin, 
  • Pages: 396-406
  • First Published: 14 December 2022
Open Access

Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population

Beatriz Núñez-García,  Mariola Blanco Clemente,  Juan Cristóbal Sánchez,  Ana Royuela,  Blanca Cantos Sánchez de Ibargüen,  Miriam Méndez,  Jorge V. López-Ibor,  Marta Martínez,  Cristina Traseira,  Yago Garitaonaindia,  Ramón Aguado,  Virginia Calvo,  María Torrente,  Consuelo Parejo,  Zaida Provencio,  Mariano Provencio, 
  • Pages: 407-414
  • First Published: 19 March 2023

Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial

Alberto Biggi,  Stephane Chauvie,  Federico Fallanca,  Luca Guerra,  Fabrizio Bergesio,  Massimo Menga,  Andrea Bianchi,  Michele Gregianin,  Agostino Chiaravalloti,  Orazio Schillaci,  Chiara Pavoni,  Caterina Patti,  Marco Picardi,  Alessandra Romano,  Corrado Schiavotto,  Roberto Sorasio,  Simonetta Viviani,  Giorgio La Nasa,  Livio Trentin,  Alessandro Rambaldi,  Andrea Gallamini, 
  • Pages: 415-423
  • First Published: 19 December 2022

Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients

Arisa Asano,  Masaki Ri,  Ayako Masaki,  Yasuhiro Maeda,  Takuto Tachita,  Kentaro Hirade,  Yoshiaki Marumo,  Takahiro Nakashima,  Shinya Hagiwara,  Shiori Kinoshita,  Tomotaka Suzuki,  Tomoko Narita,  Shigeru Kusumoto,  Hirokazu Komatsu,  Hiroshi Inagaki,  Shinsuke Iida, 
  • Pages: 424-433
  • First Published: 25 November 2022

Diagnostic relevance of 2-[18F]-FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance

Teodoro Rudolphi-Solero,  Eva María Triviño-Ibáñez,  Antonio Daniel González-Jiménez,  Carlos Ramos-Font,  Rafael Ríos-Tamayo,  Angel Custodio Rebollo-Aguirre,  Rocío Sánchez-Sánchez, 
  • Pages: 434-441
  • First Published: 12 October 2022
Open Access

Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Kazutaka Sunami,  Shin-ichi Fuchida,  Kenshi Suzuki,  Masaki Ri,  Morio Matsumoto,  Chihiro Shimazaki,  Hideki Asaoku,  Hirohiko Shibayama,  Kenichi Ishizawa,  Hiroyuki Takamatsu,  Takashi Ikeda,  Dai Maruyama,  Kazunori Imada,  Michihiro Uchiyama,  Toru Kiguchi,  Satoshi Iyama,  Hirokazu Murakami,  Reiko Onishi,  Keisuke Tada,  Shinsuke Iida, 
  • Pages: 442-452
  • First Published: 26 November 2022
Open Access

Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma

Joseph Kauer,  Lilli Sophie Sester,  Katharina Kriegsmann,  Niels Weinhold,  Michael Ober,  Carsten Müller-Tidow,  Hartmut Goldschmidt,  Marc-Steffen Raab,  Sandra Sauer, 
  • Pages: 453-462
  • First Published: 21 January 2023

Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes

Wan-Hsuan Lee,  Chien-Chin Lin,  Yu-Hung Wang,  Chi-Yuan Yao,  Yuan-Yeh Kuo,  Mei-Hsuan Tseng,  Yen-Ling Peng,  Cheng-An Hsu,  Hsun-I Sun,  Yi-Kuang Chuang,  Chia-Lang Hsu,  Feng-Ming Tien,  Cheng-Hong Tsai,  Wen-Chien Chou,  Hsin-An Hou,  Hwei-Fang Tien, 
  • Pages: 463-473
  • First Published: 24 November 2022

Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis

Fuping Wang,  Haotian Zhang,  Binghong He,  Zihan Liu,  Xinxin Wu,  Yuankai Liu,  Xin Xu,  Xiaoxue Gou,  Haitao Wang,  Qiong Yang, 
  • Pages: 474-486
  • First Published: 24 November 2022

Using natural killer cell-derived exosomes as a cell-free therapy for leukemia

Aladin Samara,  Michael Anbar,  Saar Shapira,  Anna Zemlyansky,  Alla Zozovsky,  Pia Raanani,  Galit Granot,  Uri Rozovski, 
  • Pages: 487-498
  • First Published: 30 November 2022

Chemoresistance in acute myeloid leukemia: An alternative single-cell RNA sequencing approach

Po-Liang Cheng,  Tzu-Hung Hsiao,  Chung-Hsing Chen,  Miao-Neng Hung,  Pei-Pei Jhan,  Li-Wen Lee,  Ting-Shuan Wu,  Jia-Rung Tsai,  Chieh-Lin Jerry Teng, 
  • Pages: 499-509
  • First Published: 15 February 2023

Knockdown of let-7b in leukemia associated macrophages inhibit acute myeloid leukemia progression

Chen Tian,  Yueyang Li,  Junqi Si,  Junnan Kang,  Zehui Chen,  Rexidan Nuermaimaiti,  Yafei Wang,  Yong Yu,  Zhigang Zhao,  Xiaofang Wang,  Yizhuo Zhang,  Haifeng Zhao,  Hongliang Yang,  Mingjian James You,  Guoguang Zheng,  Lina Wang, 
  • Pages: 510-519
  • First Published: 29 December 2022
Open Access

Capitalizing on paradoxical activation of the mitogen-activated protein kinase pathway for treatment of Imatinib-resistant mast cell leukemia

Thomas Wilhelm,  Marcelo A. S. Toledo,  Ilka Simons,  Christian Stuth,  Vrinda Mohta,  Ronja Mülfarth,  Marcus Nitsche,  Karin Maschke-Neuß,  Susanne Schmitz,  Anne Kaiser,  Jens Panse,  Deborah Christen,  Michel Arock,  Martin Zenke,  Michael Huber, 
  • Pages: 520-534
  • First Published: 16 November 2022

Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group

Ryu Yanagisawa,  Masaharu Tamaki,  Reo Tanoshima,  Yukiko Misaki,  Naoyuki Uchida,  Satoshi Koi,  Takashi Tanaka,  Yukiyasu Ozawa,  Yayoi Matsuo,  Masatsugu Tanaka,  Kazuhiro Ikegame,  Yuta Katayama,  Ken-ichi Matsuoka,  Takahide Ara,  Yoshinobu Kanda,  Kimikazu Matsumoto,  Takahiro Fukuda,  Yoshiko Atsuta,  Motohiro Kato,  Hideki Nakasone, 
  • Pages: 535-545
  • First Published: 17 November 2022

15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study

Chen Mei,  Li Ye,  Yanling Ren,  Xinping Zhou,  Liya Ma,  Gaixiang Xu,  Weilai Xu,  Chenxi Lu,  Haiyang Yang,  Yingwan Luo,  Lingxu Jiang,  Wei Lang,  HongHu Zhu,  Jie Jin,  Hongyan Tong, 
  • Pages: 546-554
  • First Published: 14 December 2022

CASE REPORT

COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation

Lorenzo Masina,  Nicola Bianchetti,  Angela Passi,  Chiara Bottelli,  Samuele Bagnasco,  Angelica Spolzino,  Margherita Oberti,  Marco Chiarini,  Angelo Belotti,  Simone Voltolini,  Laura Faglioni,  Giuseppe Rossi,  Alessandra Tucci,  Chiara Cattaneo, 
  • Pages: 555-558
  • First Published: 14 February 2023

LETTERS TO THE EDITOR

COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients

Giovanni Del Poeta,  Roberta Laureana,  Riccardo Bomben,  Francesca Maria Rossi,  Federico Pozzo,  Eva Zaina,  Ilaria Cattarossi,  Paola Varaschin,  Paola Nanni,  Romina Boschian Boschin,  Andrea Nunzi,  Massimiliano Postorino,  Gianmario Pasqualone,  Giulia Brisotto,  Agostino Steffan,  Elena Muraro,  Antonella Zucchetto,  Maria Ilaria Del Principe,  Valter Gattei, 
  • Pages: 559-562
  • First Published: 31 December 2022

Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion

Elisabetta Metafuni,  Antonella Cingolani,  Massimo Fantoni,  Patrizia Chiusolo,  Sabrina Giammarco,  Federica Sorà,  Eugenio Galli,  Stefan Hohaus,  Francesco D’Alò,  Silvia Bellesi,  Elena Maiolo,  Eleonora Alma,  Luca Laurenti,  Idanna Innocenti,  Francesco Autore,  Maria Assunta Limongiello,  Rosaria Santangelo,  Simona Marchetti,  Rosalba Ricci,  Simona Sica, 
  • Pages: 563-566
  • First Published: 27 December 2022

Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Riccardo Moia,  Riccardo Dondolin,  Maria Stefania De Propris,  Donatella Talotta,  Samir Mouhssine,  Francesca Perutelli,  Gianluigi Reda,  Veronica Mattiello,  Gian Matteo Rigolin,  Marina Motta,  Jacopo Olivieri,  Renato Fanin,  Omar Perbellini,  Isacco Ferrarini,  Francesca Romana Mauro,  Ilaria Del Giudice,  Luca Laurenti,  Annamaria Tomasso,  Massimo Gentile,  Anna Maria Frustaci,  Alessandra Tedeschi,  Alessandro Gozzetti,  Caterina Stelitano,  Carlo Visco,  Carol Moreno,  Francesco Forconi,  Roberto Marasca,  Marta Coscia,  Davide Rossi,  Robin Foà,  Gianluca Gaidano, 
  • Pages: 567-570
  • First Published: 03 October 2022

Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas

Francesco Autore,  Alberto Fresa,  Idanna Innocenti,  Maria Ilaria Del Principe,  Raffaele Maglione,  Caterina Stefanizzi,  Sabrina Pelliccia,  Azzurra Romeo,  Giuseppe Cimino,  Elena Papa,  Laura De Padua,  Alessandro Andriani,  Andrea Mengarelli,  Agostino Tafuri,  Concetta Ditto,  Francesca Romana Mauro,  Giovanni Del Poeta,  Luca Laurenti, 
  • Pages: 571-573
  • First Published: 23 March 2022

Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study

Marzia Varettoni,  Silvia Zibellini,  Michele Merli,  Daniela Drandi,  Cristina Jiménez,  Daniela Furlan,  Virginia Valeria Ferretti,  Nicole Fabbri,  Irene Dogliotti,  Chiara Varraso,  Martina Ferrante,  Emilia Cappello,  Veronica Peri,  Chiara Cavalloni,  Michela Borriero,  Giulia Vittoria Facchetti,  Simone Ferrero,  Luca Arcaini,  Ramon Garcia-Sanz, 
  • Pages: 574-577
  • First Published: 11 October 2022

The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma

Ning Xu,  Erin Yu,  Nicole Ng,  Mingjie Li,  Sean Bujarski,  Ava Hekmati,  Isabella Nassir,  Tara Hekmati,  Janna Yu,  David Daniely,  Cathy S. Wang,  Clara Kim,  Haiming Chen,  James R. Berenson, 
  • Pages: 578-582
  • First Published: 31 August 2022

Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Melanie Maechler,  Ulrike Bacher,  Michael Daskalakis,  Henning Nilius,  Michael Nagler,  Behrouz Mansouri Taleghani,  Barbara Jeker,  Thomas Pabst, 
  • Pages: 583-586
  • First Published: 03 August 2022

The impact of CD56 expression in smoldering myeloma patients on early progression

Laura Notarfranchi,  Roberta Segreto,  Rosanna Vescovini,  Anna Benedetta Dalla Palma,  Valentina Marchica,  Jessica Burroughs-Garcia,  Denise Toscani,  Giannalisa Todaro,  Vincenzo Raimondi,  Nicolas Thomas Iannozzi,  Sabrina Bonomini,  Gabriella Sammarelli,  Luisa Craviotto,  Mario Pedrazzoni,  Paola Storti,  Nicola Giuliani, 
  • Pages: 587-589
  • First Published: 28 November 2022

Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105

Tomotaka Suzuki,  Dai Maruyama,  Ryunosuke Machida,  Tomoko Kataoka,  Noriyasu Fukushima,  Nobuyuki Takayama,  Rie Ohba,  Ken Omachi,  Yoshitaka Imaizumi,  Masahito Tokunaga,  Hiroo Katsuya,  Isao Yoshida,  Kazutaka Sunami,  Mitsutoshi Kurosawa,  Nobuko Kubota,  Hiroaki Morimoto,  Miki Kobayashi,  Kazuhito Yamamoto,  Yoshihiro Kameoka,  Yoshitoyo Kagami,  Takayuki Tabayashi,  Masaki Maruta,  Tsutomu Kobayashi,  Shinsuke Iida,  Hirokazu Nagai, 
  • Pages: 590-593
  • First Published: 23 November 2022

Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions

Kai Sun,  Wen-Min Chen,  Xu Wang,  Xiao-Su Zhao,  Ling-Di Li,  Yue Hao,  Jun Wang,  Nan Xu,  Qian Jiang,  Hao Jiang,  Lan-Ping Xu,  Yu Wang,  Xiao-Hui Zhang,  Xiao-Jun Huang,  Ya-Zhen Qin, 
  • Pages: 594-597
  • First Published: 14 December 2022

Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates

Junying Wu,  Wenjun Zhang,  Peihong Zhang,  Tiejun Qin,  Zefeng Xu,  Qi Sun,  Yujiao Jia,  Shiqiang Qu,  Bing Li,  Huijun Wang,  Lijuan Pan,  Jinqin Liu,  Yudi Zhang,  Xin Yan,  Robert Peter Gale,  Zhijian Xiao, 
  • Pages: 598-602
  • First Published: 20 October 2022